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Coincidence of increased soluble 
interleukin-2 receptors, diminished 
natural killer cell activity and 
progressive disease in cutaneous T-
cell lymphomas 
In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical 
course was documented by determination of a tumour burden index 
(TBI) on entering the study and six months later. In addition to the first 
TBI, soluble interleukin-2 receptor levels (slL-2R) in the serum were 
determined using an ELISA technique in 23 patients. In 18 patients 
natural killer cell (NK) activity was assessed by a 4 h chromium-51 
release assay. Statistical analysis revealed a negative correlation 
between N K activity and an increase of TBI as well as NK activity and 
slL-2R. Furthermore, there was a strong positive correlation between 
the increase of TBI and slL-2R. slL-2R and NK activity might be 
prognostic factors in CTCL patients. 
Keywords: cutaneous T-cell lymphomas, soluble interleukin-2 recep-
tor, natural killer cell activity, prognostic factors. Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lym-phoproli ferative disorders originat-
ing in the skin. In general , the term desig-
nates a cl inical ly, histologically and phe-
notypically var iable spectrum of diseases 
which are slowly progressive and show 
striking interindividual differences [1]. 
An increased risk of second malignancy 
[2] and a decrease in natural kil ler cell 
activity [3, 4] indicate imbalanced im-
munofunctions in these patients. Recently, 
we and others [5, 6] reported elevated 
serum levels of soluble interleukin-2 
receptors (TAC-protein) in some of these 
patients. Yet, the b io logical relevance of 
this phenomenon is unclear. 
In the present study we analysed the 
interactions of N K activity, slL-2R and the 
cl inical outcome in CTCL patients. 
Table I. Patients characteristics: slL-2R, NK activity, and clinical course described by A TBI 
Pat. 
(n = 24) 
Stage 
TNM[19] 
Histol. diagnosis Pretreatment therapy during 
follow-up period 
(6 months) 
slL-2R 
(U/ml) 
(n = 23) 
Spec, lysis 
(%) 
(n = 18) 
A TBI 
(n = 24) 
GE IIA low-grade peripheral e.b.r 
e. ster. 
e. ster. 1690 5.0 18 
HE MB low-grade peripheral e. ster. e. ster. 385 13.0 5 
WA IA low-grade peripheral e. ster. e. ster. 405 16.5 0 
BA IIA low-grade peripheral e. ster. e. ster. 330 4.0 0 
H O IIB high-grade peripheral MTX, IFN-a MTX, e. ster. 538 30.7 0 
PUVA 
ST IIB low-grade peripheral BCNU, topical, BCNU topical 3000 6.4 30 
e. ster. e. ster. 
Tl III low-grade peripheral e. ster. BCNU topical 1320 4.0 12 
KA IIA low-grade peripheral e. ster., IFN-a e. ster. 3570 6.0 20 
KAI IIB high-grade peripheral PUVA, e. ster. e. ster. 10700 6.0 20 
KE IIA low-grade peripheral e. ster. e. ster. 1190 21.9 20 
SCH IA low-grade peripheral e. ster. e. ster. 950 10.5 0 
H O IVB low-grade peripheral PUVA, e. ster. e. ster., MTX 9230 n.d. 40 
BCNU, MTX 
I RE IIA high-grade peripheral e. ster. e. ster. 720 15.0 0 
TR IA low-grade peripheral PUVA, e. ster. IFN-a, e. ster. 800 42.3 0 
GEI IIB high-grade peripheral e. ster. e. ster. 570 n.d. 0 
BET IIA low-grade peripheral none PUVA 7330 2.3 20 
HER IA low-grade peripheral PUVA, e. ster. e. ster. 1110 6.9 0 
KG IB low-grade peripheral e. ster. e. ster. 650 24.7 2 
prednimustine 
VA IIB low-grade peripheral e. ster. e. ster. 300 22.5 0 
GR IA low-grade peripheral e. ster. BCNU topical 790 n.d. 0 
D O IVA low-grade peripheral PUVA, e. ster. e. ster. 12300 n.d. 40 
KUN IVA low-grade peripheral PUVA, e. ster. e. ster. 1190 n.d. 40 
Yl IA low-grade peripheral PUVA, e. ster. e. ster. 510 n.d. 0 
WAL IA high-grade peripheral none e. ster. n.d. 19.8 0 
MTX: methothrexate, BCNU: carmustine, IFN-a: interferon-a2a, e. ster.: external steroids, e.b.r.: electron beam radiation, n.d.: not done. 
Patients and methods 
Patients 
Twenty four patients with histologically 
proven CTCL in different stages were 
investigated. Before entering the study, 
systemic treatment had been stopped for 
at least two weeks. Physical examinations 
were done on day 0 and repeated six 
months later (for al l 24 patients). Staging 
procedures and histological c lassi f ica-
tion were done accord ing to the recom-
mendations for staging and therapy of 
cutaneous lymphomas of the European 
Organ iza t ion for Research and Treat-
ment of Cancer , cutaneous lymphoma 
project group [7]. O n day 0. per ipheral 
b lood mononuclear cells for Cr release 
assay were taken in 18 patients, and 
serum samples were col lected in 23 
patients. Patients' characteristics includ-
ing pretreatment and therapy during the 
fol low-up per iod are summarized in 
Table I. Therapy in the fo l low-up per iod 
was app l ied accord ing to the cl in- ical 
necessities. 
number 
of patients 
10 
10 
slL-2R < 1000 U slL-2R > 1000 U 
patients with progressive disease (ATBI > 10) 
patients with stable disease (ATBI < 10) 
Figure 1. Clinical outcome according to soluble interleukin-2 receptor serum levels. 
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Clinical course 
In order to estimate the cutaneous tumour 
mass in a semiquantitative manner, a 
tumour burden index was introduced. 
Physical examinations were done by one 
investigator, only. The percentage of 
involved skin was documented using the 
rule of the nines. Speci-f ic skin lesions 
were differentiated in patches (flat 
lesions, diameter larger than 1 cm), p la -
ques (flat or slightly elevated lesions with 
increased consistency) and tumours 
(large nodular lesions, diamter larger 
than 1 cm) [7]. The extension of tumours, 
patches and plaques was noted and the 
tumour burden index (TBI) was calculated 
as: 
tumour plaque patch 
TBI = x% x 4 + x% x 2 + x% x 1 
x% = involved skin in % 
Under these conditions the maximal 
achievable TBI was 400. In our patients 
the TBI was 41 ± 59 (mean ± standard 
deviat ion, minimal 2, maximal 280). 
The cl inical course of progressing 
patients was determined by the difference 
of the tumour burden index (A TBI) at day 
0 and six months later. 
It was calculated as: 
A TBI = TBI 6 - TBI 0 ; 
TBI* = after six months, TBI 0 = TBI day 0. 
Patients with a stable disease or regress-
Statistical tests 
A computerized correlation analysis was 
performed using a new statistical prog-
ramme (MEDAS) developed by Grund C , 
Haubitz I. and Rausche A . Institute for 
Biostatistics, University of Wurzburg. 
Correlat ion between slL-2R and N K acti-
vities was analysed by the calculat ion of 
Spearman's correlat ion coefficient, p. 
Correlat ion between ATBI and slL-2R 
and N K activity, respectively, was deter-
mined by the calculat ion of Kendal 's cor-
relation coefficient, r. 
Results 
The results of slL-2R, N K activity and 
cl inical course are summarized in Table I. 
Statistical analysis of our data revealed 
correlations between N K activity, slL-2R 
and disease progression, which was 
descr ibed by the ATBI . 
There was a negative correlation 
between N K activity and ATBI (r = 
-0 .3492 , P< 0.05). A strong positive cor-
relation was found between slL-2R and 
Soluble interleukin-2 receptors 
Soluble interleukin-2 receptors (slL-2R) in 
the serum were determined by sandwich 
ELISA (T Cel l Sciences Inc., Cambr idge, 
USA) [8]. The test employs two non-
competing murine monoclonal anti-
bodies to the a-chain of human IL-2R. It 
was done according to the manufactur-
er's instructions. The microtiter plates 
were read at 490 nm using a Dynatech 
MR 700 microplate reader. Units of slL-2R 
were calculated from a standard curve 
constructed on the basis of a supernatant 
from phytohemagglutinin-stimulated 
peripheral b lood mononuclear cells. 
Interassay variation was 5%. 
Natural killer cell activity 
Peripheral mononuclear cells (PMC) 
were separated by Ficol l -Hypaque cen-
trifugation. N K activity was determined in 
a 4 h 5 1 C r release assay as previously 
descr ibed [9], using the NK-sensit ive 
erythroblastoma cell line K562 as target 
cells. The effectontarget ratio was 40 : 1. 
Spon-taneous release was assessed by 
incubating label led K 562 in medium 
alone, and total release was evaluated by 
a solution of SDS. After harvesting the 
supernatants using a Skatron filterstick 
system, radioactivity was measured in a 
Pharmacia gamma-counter. 
Specific lysis (SL) was calculated as: 
0.3492, P < 0.05). A strong positive corre-
lation was found between slL-2R and 
ATBI (r = 0.6091, P < 0.0005). N o corre-
lation between staging and slL-2R or 
staging and N K activity was observed. 
N K activity and slL-2R showed a negative 
correlation (p = - 0 . 5 4 2 3 , P < 0.03). 
Analysing the reliability of slL-2R as a 
prognostic factor, we suggest that a ATBI 
of at least 10 should be considered as a 
significant change. Moreover , slL-2R 
should exceed the upper normal range by 
a factor of 2 (> 1000 U/ml). Under these 
conditions the specificity of slL-2R for 
tumour progression was 90.0% (n = 11). 
There was no false-posit ive value, 
indicating high sensitivity (Fig. 1). 
Discussion 
Recent reports of successful transplanta-
tion of cutaneous lymphomas on natural 
kil ler cel l-depleted severe combined 
immunodeficient (SCID) mice [10] as well 
SL(7 ) M e a n experimental release - mean spontaneous release ^ 
M e a n total release - mean spontaneous release 
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as an enhanced risk of developing secon-
dary neoplasias [2] point to impaired 
immunofunctions in CTCL patients. A n a -
lysing N K activity and cl inical course in 
these patients we found a correlat ion 
between the decrease of N K activity and 
the progression of the disease. W e con-
clude that N K activity might be a prognos-
tic factor for CTCL patients. 
Elevated levels of slL-2R were found in the 
serum of patients suffering from lym-
phoprol i ferative disorders [5,6,11,12] as 
well as in the serum of patients suffering 
from inflammatory skin diseases [13]. 
Regarding the strong correlation 
between tumour progression in CTCL pa -
tients and slL-2R, we suggest that this 
soluble protein may be of high prognostic 
value. This is consistent with the detection 
of slL-2R as an unfavourable prognostic 
sign in other lymphoproli ferative disor-
ders such as Hodgkin 's disease [11] and 
lymphoblastic lymphomas [12]. 
From an immunological point of view, the 
negative correlation between slL-2R and 
N K activities offers interesting perspec-
tives. Under physiologic circumstances, 
membrane-bound and soluble forms of 
the T A C protein are observed after T-cell 
stimulation, for example by antigen pre-
senting cells and interleukin 1. As a con-
sequence, the stimulated T lymphocytes 
produce interleukin-2 [14]. In CTCL 
patients this mechanism seems to be dis-
turbed. In some CTCL patients, interleukin 
1 [15] might enhance expression of T A C 
protein, albeit, without addit ional induc-
tion of interleukin-2, which is able to res-
tore diminished N K activity [16] and is 
known to be a potent stimulating cytokine 
for N K activity [9]. This d iscordance could 
be an important factor for tumour spread-
ing. W e propose, that slL-2R might be 
responsible for the decreased N K activity 
by neutralizing interleukin-2 [17, 18] • 
Abbreviations 
CTCL: cutaneous T-cell lymphoma. 
SCID: severe combined immune 
deficiency. 
slL-2R: soluble interleukin-2 receptor. 
N K : natural ki l ler cel l . 
TBI: tumour burden index. 
Zusammenfassung 
Bei 24 Patienten mit cutanem T-Zell 
Lymphom (CTCL) wurde der klinische 
Ver lauf mittels eines "Tumor burden 
index (TBI)" bei Beginn der Beobach-
tung und sechs Monate spdter doku-
mentiert. Zusammen mit dem ersten 
TBI wurde der losl iche Interleukin-2 
Rezeptor (slL-2R) im Serum mittels 
ELISA und die naturliche Ki l lerzel l -
(NK-) Aktivitat der peripheren mono-
nukledren Zel len mittels "Cr-51 
Release A s s a y " bestimmt. Die statistis-
che Auswertung der drei Parameter 
e rgab eine negative Korrelat ion zwis-
chen NK-Akt iv i tat und Zunahme des 
TBI, sowie zwischen NK-Akt iv i tat und 
slL-2R. Auf ierdem fand sich eine hoch-
signifikante Korrelat ion zwischen sIL-
2R und Zunahme des TBI. slL-2R und 
NK-Akiv i td t sind mogl icherweise von 
prognostischer Bedeutung bei Patien-
ten mit CTCL . 
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